Credit: MD Anderson Cancer Center
HOUSTON The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center s Therapeutics Discovery division, appears to be well-tolerated with successful target inhibition and early signs of anti-tumor activity in a biomarker-driven Phase I trial. Interim results of the study will be presented at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting on June 4.
On the trial, 17 of 20 evaluable patients achieved a best response of stable disease, with a disease control rate of 60% at 12 weeks. Six patients with biomarker-defined advanced cancers had meaningful durable disease stabilization for greater than six months, with evidence of tumor shrinkage.
Operator
Good day ladies and gentlemen and welcome to Oncternal s Therapeutics Inc. first-quarter 2021 financial results call. [Operator instructions] At this time it is my pleasure to turn the floor over to your host Richard Vincent. Sir the floor is yours.
Rich Vincent
Chief Financial Officer
Thank you, Melinda. Good afternoon, everyone, and thank you for joining us today. Joining me on the call this afternoon are our president and CEO, Dr. James Breitmeyer; and our acting CMO, Dr.
Edwina Baskin-Bey. We welcome all of you. Today s call includes a business update and discussion of our 2021 first-quarter financial results which will be followed by Q&A. Today s press release and replay of today s earnings call will be available on the Investor Relations section of Oncternal s website for at least the next 30 days.
Merck Announces First-Quarter 2021 Financial Results
First-Quarter 2021 Sales Were $12.1 Billion, In-Line with First-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Declined 1% First-Quarter 2021 Sales Reflect Strong Underlying Performance of KEYTRUDA, Lynparza, BRIDION and Animal Health, Which Was Offset by COVID-19 Pandemic Impacts to Patient Access, Particularly for Vaccines First-Quarter 2021 GAAP EPS Was $1.25; First-Quarter Non-GAAP EPS Was $1.40 … First-Quarter 2021 Sales Were $12.1 Billion, In-Line with First-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Declined 1% First-Quarter 2021 Sales Reflect Strong Underlying Performance of KEYTRUDA, Lynparza, BRIDION and Animal Health, Which Was Offset by COVID-19 Pandemic Impacts to Patient Access, Particularly for Vaccines First-Quarter 2021 GAAP EPS Was $1.25; First-Quarter Non-GAAP EPS Was $1.40
Historic, New CEO at American Cancer Society
April 14, 2021
Karen E. Knudsen, M.B.A., Ph.D., will become the first female chief executive officer (CEO) in the 107-year history of the American Cancer Society (ACS). She will be the first scientific and oncology researcher to serve in the top staff position in the modern era.
Knudsen also will become CEO of the American Cancer Society Cancer Action Network (ACS CAN), its advocacy affiliate, effective June 1. She will succeed Gary Reedy, who is retiring and has served as both organizations’ CEO since 2015.
The hiring of a female CEO signals a new era for ACS, where all of its past top leaders were men, even though its Women’s Field Army was credited for building what became the modern American Cancer Society, according to an ACS announcement.